Compounding & Legal Disclosures
503A compounding only. Aryo Health LLC exclusively partners with U.S.-licensed 503A compounding pharmacies to dispense compounded medications for our members. A 503A pharmacy is a traditional state-licensed compounding pharmacy regulated under Section 503A of the Federal Food, Drug, and Cosmetic Act. 503A pharmacies prepare patient-specific compounded medications pursuant to a valid prescription from a licensed prescriber for an identified individual patient. Compounded drugs are not reviewed or approved by the FDA for safety, effectiveness, or quality.
Reason for compounding. A clinically appropriate reason for compounding (for example, a documented allergy or intolerance to an inactive ingredient in the commercially available product, a needed dose or strength not commercially available, or a documented drug shortage) must be discussed with and determined by your Aryo-affiliated licensed provider during your consultation. Eligibility for any compounded medication — including compounded semaglutide and tirzepatide — is decided solely by the prescribing clinician based on your medical history, current medications, and clinical need. Submitting an intake does not guarantee a prescription.
General. Aryo Health LLC is a telehealth platform and is not a pharmacy or a manufacturer. GLP-1 medications are physician-prescribed; results vary and are not guaranteed. Do not use if you have a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Discuss all risks, benefits, and alternatives with your clinician before starting treatment.
© 2026 Aryo Health LLC. All rights reserved.